Other agents, including HQP8361, dictamnine, and the natural compound berberine, have likewise shown promise in countering MET-driven osimertinib resistance by inhibiting MET signaling and inducing tumor cell apoptosis [292,293,294]. This evidence concerns the gene MET and neoplasm.